<DOC>
	<DOCNO>NCT00902122</DOCNO>
	<brief_summary>This multicenter , open-label , randomize , active-controled , phase IV study local direct intra-tumor injection rAd-p53 monotherapy , concurrent radioactive iodine , combination surgery treatment advance malignant thyroid tumor .</brief_summary>
	<brief_title>rAd-p53 Gene Therapy Advanced Malignant Thyroid Tumors</brief_title>
	<detailed_description>Primary objective study determine efficacy profile rAd-p53 intra-tumor injection alone , concurrent radioactive iodine , combination surgery treatment advance malignant thyroid tumor ( stage III IV ) include target lesion complete response rate ( LCR ) overall target lesion response rate ( OLR ) , response duration ( RD ) , progress-free survival ( PFS ) . The secondary objective study investigate overall response rate ( OPCR ) overall complete response rate ( OCR ) , overall survival ( OS ) , ECOG , safety rAd-p53 monotherapy combine radioactive iodine , surgery .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Li-Fraumeni Syndrome</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>1 . Advanced stage thyroid malignant tumor ( stage III VI ) 2 . At least one target tumor inject study drug , large diameter great 2 cm 3 . Histologically confirm Oral Maxillofacial malignant tumor 4 . No prior chemotherapy , radiotherapy biological tumor therapy 2 week 5 . Age : 1885 year old 6 . Expected survive 12 week 7 . ECOG:02 8 . Neutrophils≥1.5×109/L , Platelet≥ 80×109/L , Hb≥80g/L , bilitubin≤2mg/dl , ALT AST ≤2×institutional upper limit normal , Cr ≤1.5×institutional upper limit normal , coagulation test ( PTT INR ) within normal range 9 . Subject provide sign informed consent 1 . Hypersensitive study drug 2 . Tumor ( ) locate close important blood vessel nerve , affect injection 3 . With coagulation bleed disorder 4 . With uncontrolled , intercurrent illness include limited symptomatic neurological illness , symptomatic congestive heart failure , unstable angina pectoris , significant pulmonary disease hypoxia , psychiatric illness 5 . Local infection close injection site systemic infection 6 . Pregnant lactate 7 . Principle investigator consider suitable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>p53 gene</keyword>
	<keyword>thyroid</keyword>
	<keyword>gene therapy</keyword>
	<keyword>malignant tumor</keyword>
</DOC>